News · 26 weeks36-50%
2026-03-012026-08-23
Mix1690d
- SEC Filings11(69%)
- Other5(31%)
Latest news
25 items- PRPresenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live streamMIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter All times are in Eastern Time Presenting Today – Wednesday August 19, 2026 8:30Virtual Lobby opens.Register for the Con
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- PRPresenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live streamMIAMI, Aug. 18, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter All times are in Eastern Time Day 1 - WednesdayAugust 19, 2026 8:30Virtual Lobby opens.Register for the Conference. I
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- PRImmuron CEO, Steven Lydeamore presentation at Kalkine Media WebinarMELBOURNE, Australia, July 20, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Kalkine Media Webinar on Monday, 20th July 2026 (12:30pm Australian Eastern Time). A copy of the presentation slide deck is available on the Company’s website: https://investors.immuron.com.au/announcements/7639968 This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT:Steven LydeamoreChief Executive Officersteve@immuron.com About ImmuronImmuron Limited ((ASX: IMC, NASDAQ:IMRN), is an Australian biopharmaceutical company focused on developing and commerci
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- PRImmuron FY26 Sales - Four Consecutive Quarters of Growth over Prior YearSales Highlights (unaudited):Global FY26 sales AUD$7.7 million up 6% on prior comparative period (pcp)2H FY26 sales AUD$3.5 million up 7% on pcp4Q FY26 sales AUD$2.0 million up 2% on pcp Australia FY26 sales AUD$5.8 million up 10% on pcp2H FY26 sales AUD$2.5 million up 6% on pcp4Q FY26 sales AUD$1.6 million up 1% on pcp Canada FY26 sales AUD$0.2 million down 55% on pcp2H FY26 sales AUD$0.1 million up >1000% on pcp4Q FY26 sales up 376% on pcp USA FY26 sales AUD$1.8 million up 7% on pcpFY26 sales USD$1.2 million up 13% on pcp 2H FY26 sales AUD$0.9 million down 1% on pcp2H FY26 sales USD$0.6 million up 9% on pcp
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- PRImmuron Advances IMM-529 (Clostridioides difficile infection) Partnering StrategyKey Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering StrategyImmuron is seeking a partner to support clinical development through regulatory approval and commercializationImmuron has U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) applicationIND 32095 is Immuron’s Investigational new drug (IND) application for clinical development of IMM-529 as a product to specifically prevent or treat Clostridioides difficile infection (CDI) MELBOURNE, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to announce that it has engaged Pullan Consulting to provide business development services
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- INSIDERNew insider Palumbo Flavio claimed ownership of 1,142,909 units of Ordinary Shares (SEC Form 3)3 - Immuron Ltd (0001660046) (Issuer)
- INSIDERNew insider Pollock Daniel Jude claimed ownership of 743,230 units of Ordinary Shares (SEC Form 3)3 - Immuron Ltd (0001660046) (Issuer)
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- PRPresenting on Emerging Growth Conference 92 Day 2 on May 7; Register to live streamMIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 92nd Emerging Growth Conference on May 6 & 7, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter. Presenting today – Wednesday, May 6, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go
- PRPresenting on Emerging Growth Conference 92 Day 1 on May 6; Register to live streamMIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on May 6 & 7, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayMay 6, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to the re
- INSIDERSEC Form 3 filed by new insider Brennan Paul Gerard3 - Immuron Ltd (0001660046) (Issuer)
- SECSEC Form 6-K filed by Immuron Limited6-K - Immuron Ltd (0001660046) (Filer)
- INSIDERNew insider Kanellos Jerry claimed ownership of 333,000 units of Ordinary Shares (SEC Form 3)3 - Immuron Ltd (0001660046) (Issuer)
- INSIDERNew insider Lydeamore Steven George claimed ownership of 3,155,047 units of Ordinary Shares (SEC Form 3)3 - Immuron Ltd (0001660046) (Issuer)
IMRN FAQ
6 questionsWhat does Immuron Limited do?
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver...Where does IMRN stock trade?
Immuron Limited (IMRN) is listed on NASDAQ.What sector and industry is IMRN in?
Immuron Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Immuron Limited go public?
Immuron Limited (IMRN) completed its IPO in 2017.What companies are similar to IMRN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IMRN side-by-side with any of them on Quantisnow.How can I track IMRN on Quantisnow?
Quantisnow aggregates Immuron Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMRN to receive live email and push alerts on every new disclosure.